COMMON STOCK PURCHASE WARRANT IMPRIMIS PHARMACEUTICALS, INC. Warrant Shares: _______ Initial Exercise Date: April 30, 2012Imprimis Pharmaceuticals, Inc. • April 27th, 2012 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the three year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Imprimis Pharmaceuticals Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 27th, 2012 • Imprimis Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of the Effective Date, between Imprimis Pharmaceuticals Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
Advisory AgreementAdvisory Agreement • April 27th, 2012 • Imprimis Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This advisory agreement (the “Agreement”) is made and entered into as of April 1, 2012 (the “Effective Date”), by and between (a) Imprimis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (b) Dr. Robert Kammer, an individual (the “Consultant”).
IMPRIMIS PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • April 27th, 2012 • Imprimis Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This EMPLOYMENT AGREEMENT (the “Agreement”) is made effective as of April 1, 2012 (the “Effective Date”), by and between Imprimis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Mark L. Baum (“Executive”):
PROMISSORY NOTE CONVERSION AGREEMENTPromissory Note Conversion Agreement • April 27th, 2012 • Imprimis Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS PROMISSORY NOTE CONVERSION AGREEMENT (the “Agreement”), is effective as of April 20, 2012, by and between Imprimis Pharmaceuticals, Inc. (the “Company”) and DermaStar International, LLC (the “DermaStar”) (Individually, the Company and DermaStar may be referred to herein as a “Party,” and collectively as the “Parties”).
